Home › Company Timeline

Company Timeline

The MDNA journey began in 2001 with a research collaboration between scientists from universities on opposite sides of the Atlantic. We’ve come a long way since then. You can see many of the landmarks that have brought us to today below.

2002
Genesis Genomics is founded
2004
Biomarker for Prostate Cancer discovered
2008
Proof of concept studies completed for 11 different cancers
2008
American Journal of Clinical Pathology publication – Mtgenome Deletion Aids in the Identification of False- and True-Negative Prostate Needle Core Biopsy Specimens
2010
Genesis Genomics rebrands as Mitomics
2010
Prostate Cancer and Prostatic Disease publication – Accurate Prediction of Repeat Biopsy Outcomes by a mtDNA Deletion Assay
2011
Prostate Core Mitomic™ Test launched
2014
MDNA acquired the intellectual property and assets of Mitomics
2015
MDNA commences clinical validation of Mitomic™ Prostate Test in collaboration with the University of Cambridge, UK
2016
Mitomic™ Prostate Core Test Clinical Utility Paper published in American Health and Drug Benefits
2016
Collaboration agreement with the University of Oxford for development of Endometriosis Test, a blood-based liquid biopsy test for Endometriosis
2017
A single mitochondrial DNA deletion accurately detects significant prostate cancer in men in the PSA "grey zone". published in the World Journal of Urology
2018
MDNA introduces strategy to develop our Mitomic ™ tests in 'kit' form to allow easy use of the tests worldwide
2019
Mitochondrial DNA deletions accurately detect endometriosis in symptomatic females of child-bearing age published in Biomarkers in Medicine
2020
MDNA validates a new cfDNA blood collection device for commercial use
2020
MDNA's UK laboratory launches a commercial COVID-19 PCR testing service to help fight the pandemic in workplaces and sports organisations
2021
MDNA is UKAS accredited as an ISO 15189 laboratory and included on UK Government websites as a provider of COVID 19 testing.